Enovis Corporation (NYSE:ENOV) Stock Has Consensus Target Price of $37.25 According to Analysts

Enovis Corporation (NYSE:ENOV) has been assigned an average rating of “Moderate Buy” from the twelve research firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and ten have given a buy recommendation to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $37.25.

Several equities research analysts recently commented on ENOV shares. Citigroup reaffirmed a “market outperform” rating on shares of Enovis in a report on Wednesday, September 2nd. Wells Fargo & Company lowered their price objective on Enovis from $39.00 to $33.00 and set an “overweight” rating on the stock in a research note on Wednesday, September 2nd. Wall Street Zen upgraded Enovis from a “hold” rating to a “buy” rating in a report on Saturday. Citizens Jmp cut their target price on Enovis from $55.00 to $47.00 and set a “market outperform” rating for the company in a research note on Wednesday, September 2nd. Finally, Zacks Research raised Enovis from a “strong sell” rating to a “hold” rating in a research note on Wednesday, July 29th.

Insider Transactions at Enovis

In other news, insider Oliver Engert bought 2,660 shares of Enovis stock in a transaction on Friday, September 4th. The shares were bought at an average cost of $18.80 per share, with a total value of $50,008.00. Following the completion of the purchase, the insider directly owned 63,898 shares of the company’s stock, valued at approximately $1,201,282.40. This trade represents a 4.34% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Damien Mcdonald bought 13,035 shares of Enovis stock in a transaction on Friday, September 4th. The shares were purchased at an average cost of $19.15 per share, for a total transaction of $249,620.25. Following the completion of the purchase, the chief executive officer directly owned 247,077 shares of the company’s stock, valued at $4,731,524.55. This trade represents a 5.57% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders purchased 23,293 shares of company stock valued at $449,599 in the last three months. 2.90% of the stock is currently owned by insiders.

Institutional Trading of Enovis

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Paradigm Capital Management Inc. NY lifted its position in shares of Enovis by 70.2% during the first quarter. Paradigm Capital Management Inc. NY now owns 1,776,715 shares of the company’s stock worth $40,420,000 after purchasing an additional 732,917 shares during the last quarter. Private Management Group Inc. increased its holdings in Enovis by 38.8% in the second quarter. Private Management Group Inc. now owns 1,365,082 shares of the company’s stock valued at $28,257,000 after buying an additional 381,705 shares during the last quarter. Allspring Global Investments Holdings LLC increased its holdings in Enovis by 38.0% in the first quarter. Allspring Global Investments Holdings LLC now owns 1,045,360 shares of the company’s stock valued at $24,430,000 after buying an additional 287,687 shares during the last quarter. Front Street Capital Management Inc. raised its stake in Enovis by 106.1% during the first quarter. Front Street Capital Management Inc. now owns 746,056 shares of the company’s stock valued at $16,973,000 after buying an additional 384,124 shares in the last quarter. Finally, Quantinno Capital Management LP raised its stake in Enovis by 130.8% during the first quarter. Quantinno Capital Management LP now owns 604,500 shares of the company’s stock valued at $13,752,000 after buying an additional 342,556 shares in the last quarter. Institutional investors and hedge funds own 98.45% of the company’s stock.

Enovis Price Performance

Shares of Enovis stock opened at $20.85 on Friday. The company has a current ratio of 1.98, a quick ratio of 1.00 and a debt-to-equity ratio of 0.84. The stock has a market capitalization of $1.20 billion, a price-to-earnings ratio of 6.16 and a beta of 1.31. Enovis has a 1-year low of $16.70 and a 1-year high of $32.41. The firm’s 50-day moving average price is $19.82 and its two-hundred day moving average price is $23.05.

Enovis (NYSE:ENOV) last posted its earnings results on Thursday, August 6th. The company reported $0.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.85 by $0.05. Enovis had a negative net margin of 47.96% and a positive return on equity of 12.03%. The company had revenue of $582.78 million during the quarter, compared to analysts’ expectations of $581.84 million. During the same quarter in the previous year, the company posted $0.79 earnings per share. Enovis’s quarterly revenue was up 3.2% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, equities analysts predict that Enovis will post 3.15 earnings per share for the current fiscal year.

Enovis Company Profile

Enovis Corporation (NYSE: ENOV) is a medical technology company that develops, manufactures and distributes products designed to improve patient recovery, mobility and quality of life. Its portfolio serves orthopedic, sports medicine, physical therapy and rehabilitation markets, as well as other areas of musculoskeletal care.

The company’s products include orthopedic implants and surgical technologies, braces and supports, cold and compression therapy systems, electrotherapy and rehabilitation equipment, and other solutions used by hospitals, surgeons, physical therapists, athletic trainers and patients.